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GB virus C/hepatitis G virus (GB V-C/HG V) is a positive-sense,
single-stranded RNA virus belonging to the family Flaviviridae and
is distantly related to hepatitis C virus (HC 13 GB V-C/HG V can be
transmitted by the parenteral and the sexual route1 4 Among
Thdividuals infected with human immunodeficiency virus type 1
(HI-i) by the sexual route, we and others have demonstrated a high
prevalence of GB V-C/HG V infection.58Recently, Woolley and col
leagues reported that AIDS patients co-hfected with GB V-C/HG V
had a significantly lower mean CD4 cell count than AIDS patients
without GB V-C/HG V infection,9suggesting that GB V-C/HG V anti
body may be lost with progression to AIDS. To our knowledge no
data are available on the loss of antibody agathst GBV-C/HGV in
AIDS patients. We now report on an HI V-infected patient who
exhibited gradual loss of IgG antibodies against GB V-C/HG V, as
well as HCI.4 with progression of HIV disease.
Case Report
A 35-year-old Caucasian woman, presumed to have been infected
by injection drug use (IDU) with HIV subtype B in 1994, was first
seen in October 1995 in our Women’s Clinic, which provides
medical and psychosocial services to HIV-infected women. At the
initial visit, CD4 and CD8 counts were 197 and 435 X 106 cells/L,
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respectively. Plasma was negative for GBV-CIHGV and HCV
RNA, as determined by reverse transcription-polymerase chain
reaction (RT-PCR) using oligonucleotide primers spanning 377-bp
and 257-bp of the 5’-untranslated region of GBV-C/HGV and HCV,
respectively.8 However, plasma was positive for IgG antibodies
against GBV-C/HGV and HCV, as measured by enzyme-linked
immunosorbent assay (ELISA), with optical density (OD) readings
of 1.14 and 2.60, respectively. Hepatitis B virus surface antigen and
core antibody were also detected, and liver enzyme levels were
abnormal: alanine aminotransferase, 71 lUlL; aspartate transami
nase, 118 lU/L; gamma glutamyl transferase, 73 lU/L; and alkaline
phosphatase, 294 lUlL. Low-grade squamous intraepithelial lesion
(SIL) found on initial visit progressed to high-grade SIL in April
1997, and human papillomavirus 18 was detected by PCR in
cervicovaginal lavage cells.
In April 1996, she was diagnosed with Mycobacterium avium
complex and esophageal candidiasis, and in August 1996, HIV RNA
burden was 230,290 copies/mL (Amplicor HIV-1 Monitor Test,
Roche Diagnostic System, Somerville, NJ) with CD4 and CD8
counts of 48 and 145 X 106 cellslL, respectively. In October 1996,
highly active antiretroviral therapy (HAART) was started with the
addition ofIndinavir to D4T and 3TC. The patient was noncompliant
to HAART and in February 1997, cytomegalovirus-associated
retinitis was diagnosed in her right eye. A month later, HIV RNA
burden was 152,967 copies/mL with CD4 count of 26 X 106 cellslL.
In April 1997, with increasing compliance to HAART, her HIV
plasma viral RNA decreased to 27,334 copies/mL, with CD4 and
CD8 counts of 160 and 217 X 106 cells/L, respectively. HIV RNA
viral load was 230,000 copies/mL in September 1997. In October
1997, non-Hodgkin’s lymphoma and HIV-associated myelopathy
were diagnosed with a CD4 count of 22 X 106 cells/L, after which
her health deteriorated rapidly, and she died in January 1998. At
autopsy, blood and peritoneal fluid were collected.
Plasma collected over a 27-month period were tested in triplicate
by ELISA for IgG antibodies against GBV-C/HGV (Ortho HGV
CHOe2 ELISA Test System, Ortho Clinical Diagnostics, Raritan,
NJ), HCV (Ortho HCV Version 3.0 ELISA Test System, Ortho
Clinical Diagnostics) and HTV (Genetic Systems H1V-1/2 EIA,
Genetic Systems Corp., Redmond, WA). In addition, plasma were
assayed for reactivity to HIV proteins by Western blot analysis
(HIV-1 Western Blot Kit, Cambridge Biotech Corp., Rockville,
MD). To assure comparability, all plasma specimens were tested by
the above-mentioned assays at the same time. As seen in Fig. 1, the
patient lost IgG antibodies against GBV-CIHGV and HCV (positive
cutoff value, OD 0.6) between 18 to 20 months after the initial visit,
and the OD readings were 0.07 and 0.03, respectively, in the plasma
sample collected at autopsy.
Discussion
As a result of 11W-I-induced severe immunosuppression, de
pressed humoral and cellular immunity has been documented to
specific parasitic,10-2bacteriaV314 and virafl” 15-16 agents. Signifi
cantly lower levels of IgG, 1gM and IgA antibodies to Giardia
lamblia were demonstrated in AIDS patients with acute giardiasis.12
Loss of humoral immune response to Pneumocystis carinii in AIDS
patients when compared to other immunosuppressed patients or
immunocompetent controls has been documented.’3’‘ Moreover,
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progressive loss of IgG antibodies against Chiamydia pneumoniae
has been demonstrated in middle to advanced stages of HIV-1
infection.’4
In a study of 95 HIV- I-infected individuals (45 asymptomatic and
40 with AIDS), Radkowski and coworkers” demonstrated lower
antibody titers to hepatitis B surface antigen, rubella virus and
cytomegalovirus in AIDS patients when compared to
asymptomatically infected individuals. Similarly, a population-
based study of measles and measles immunization in HIV- 1-in
fected children demonstrated loss of anti-measles antibody over
time in older children and a statistically significant correlation
between lower CD4 counts and measles-mumps-rubella vaccine
nonresponsiveness.’6Finally, time-dependent HCV seroreversion
has been reported in a cohort of HIV- I-infected IDU. ‘
Loss of seroreactivity to specific HIV- 1 epitopes has also been
reported. Up to a 100-fold greater affinity to HIV- 1-specific p24 and
p17 proteins has been found in asymptomatic HIV-1-infected indi
viduals than in AIDS patients,’8suggesting that those who develop
AIDS either lose or fail to develop high-affinity antibodies early in
the infection. These data also demonstrate that the presence of low-
affinity antibody and the progressive reduction in titer of specific
antibodies are better predictors of disease onset than CD4 cell count.
Moreover, antibodies against HIV-l p24 is undetectable in 45% of
individuals by the time of AIDS diagnosis.’9 Although the patient
reported here did not exhibit a dramatic drop in IgG antibodies to
HIV- 1 as measured by ELISA, during the last 3 months before death,
there was a gradual loss of reactivity to HIV- 1 gag-encoded pro
teins, as determined by Western blot analysis (Fig. 1).
In conclusion, as seen in other opportunistic infections associated
with AIDS, AIDS patients co-infected with GBV-CJHGV may
similarly lose anti-GBV-C/HGV antibodies during progression to
AIDS.
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Fig. 1.— LongitudinalanalysisoflgGantibodyresponsetoGBV-CMGV,HCV
and HIV, asmeasuredbyEUSAandWesternblotinanAlDSpatient.
Reactivity to HIV proteins is indicated: positive, +; negative -;
indeterminate,± ELlSAcutoffswere 000.6 (4)forGBV-CIHGV
and HCV, and OD 0.2 (—f) for HIV.
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